Posts

Ultragenyx Gene Therapy DTX301 Hits Key Endpoint in Phase 3 Trial for Ornithine Transcarbamylase Deficiency

on

Ultragenyx Announces Layoff of 130 Employees Amid FDA Delays on UX111 Resubmission

on

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

on

Ultragenyx Resubmits BLA for UX111 Gene Therapy Targeting Sanfilippo Syndrome Type A to FDA

on

Ultragenyx and Mereo BioPharma Stocks Crash After Late-Stage Setrusumab Trials Fail in Osteogenesis Imperfecta

on

FDA Declines Approval of Ultragenyx's Sanfilippo Gene Therapy Due to Manufacturing Issues

on